
Join to view full profile
555 S 18th StColumbus, OH 43205
Phone+1 614-722-6200
Fax+1 614-722-3273
Dr. Sahenk is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalResidency, Neurology, 1975 - 1978
Ohio State University HospitalResidency, Internal Medicine, 1974 - 1975
Ohio State University HospitalResidency, Physical Medicine and Rehabilitation, 1972 - 1974
Hacettepe University FOMClass of 1972
Certifications & Licensure
OH State Medical License 1978 - 2028
IL State Medical License 1977 - 1984
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
- NT-3 Levels and Function in Individuals With CMT Start of enrollment: 2020 Jan 29
Publications & Presentations
PubMed
- Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study.Jerry R Mendell, Zarife Sahenk, Linda P Lowes, Megan A Iammarino, Lindsay N Alfano
Muscle & Nerve. 2026-08-01 - AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis.Burcak Ozes, Lingying Tong, Morgan Myers, Kyle Moss, Edward Son
Human Gene Therapy. 2026-07-09 - The NORAD-Pumilio regulatory axis in the evolution of inclusion body myositis.Lingying Tong, Burcak Ozes, Kyle Moss, Morgan Myers, Alexandra Hornung
Journal of Neuropathology and Experimental Neurology. 2026-04-17
Journal Articles
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, Richard Shell, JAMA Neurology
Authored Content
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular DystrophyJune 2020
Press Mentions
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2ASeptember 3rd, 2021
First Global CMT Research Convention Planned for SeptemberJune 16th, 2021
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to Its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular DystrophyMay 8th, 2019
Grant Support
- NT-3 Gene Therapy To Improve Peripheral Nerve Function Induced By Genetic DefectNational Institute Of Neurological Disorders And Stroke2010–2011
- Histopathology CoreEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
- Histopathology CoreNational Institute Of Neurological Disorders And Stroke2007–2010
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









